Literature DB >> 1365682

Ten-year follow-up of breast carcinoma in situ in Connecticut.

B A Ward1, C F McKhann, T S Ravikumar.   

Abstract

Statistics from the Connecticut Tumor Registry from 1979 to 1988 were examined, and individual medical records from 1979 to 1983 were also reviewed. Three hundred nineteen medical records were available for review, documenting 220 cases of ductal carcinoma in situ and 102 cases of lobular carcinoma in situ. In 1979, there were 33 new cases of ductal carcinoma in situ reported to the Connecticut Tumor Registry, representing 1.8% of all breast cancers. There has been a yearly increase in ductal carcinoma in situ, with 200 new cases, or 7.4% of all breast cancers, reported in 1988. Forty-eight (22%) of 217 patients with ductal carcinoma in situ had bilateral breast involvement with ductal carcinoma in situ or an invasive breast cancer. Ten (83%) of 12 mastectomy specimens from patients with ductal carcinoma in situ who presented with nipple discharge demonstrated residual tumor, suggesting a more diffuse involvement. Two of the three reported recurrences involved nipple discharge. Thirty-seven (16.8%) of the 220 patients with ductal carcinoma in situ and six (5.9%) of the 102 patients with lobular carcinoma in situ were diagnosed as having another unrelated cancer. Ongoing clinical trials will direct optimum therapy for patients increasingly diagnosed as having ductal carcinoma in situ.

Entities:  

Mesh:

Year:  1992        PMID: 1365682     DOI: 10.1001/archsurg.1992.01420120026004

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

Review 1.  Early breast cancer.

Authors:  Tomoyoshi Suzuki; Masakazu Toi; Shigehira Saji; Kazumi Horiguchi; Tomoyuki Aruga; Eiji Suzuki; Shinichiro Horiguchi; Nobuaki Funata; Katsuyuki Karasawa; Noriko Kamata
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 2.  Imaging for the diagnosis and management of ductal carcinoma in situ.

Authors:  Carl J D'Orsi
Journal:  J Natl Cancer Inst Monogr       Date:  2010

3.  What is the sensitivity of mammography and dynamic MR imaging for DCIS if the whole-breast histopathology is used as a reference standard?

Authors:  F Sardanelli; L Bacigalupo; L Carbonaro; A Esseridou; G M Giuseppetti; P Panizza; V Lattanzio; A Del Maschio
Journal:  Radiol Med       Date:  2008-07-09       Impact factor: 3.469

Review 4.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.

Authors:  P S Steeg; S E Clare; J A Lawrence; Q Zhou
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 5.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ.

Authors:  Jennifer A Ligibel; Ann Partridge; Anita Giobbie-Hurder; Mehra Golshan; Karen Emmons; Eric P Winer
Journal:  Ann Surg Oncol       Date:  2008-10-24       Impact factor: 5.344

7.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

Review 8.  In situ breast cancer.

Authors:  R S Henry-Tillman; V S Klimberg
Journal:  Curr Treat Options Oncol       Date:  2000-08

9.  Increased risk of second malignancies after in situ breast carcinoma in a population-based registry.

Authors:  I Soerjomataram; W J Louwman; M J C van der Sangen; R M H Roumen; J W W Coebergh
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

10.  The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.

Authors:  D Robinson; L Holmberg; H Møller
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.